Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of < em > FLT3 < /em > -ITD-positive AML treated with gilteritinib

We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.PMID:33631087 | DOI:10.1080/16078454.2021.1889111

Source: Hematology - February 25, 2021 Category: Hematology Authors: Takeshi Kondo Masahiro Onozawa Shinichi Fujisawa Shinpei Harada Reiki Ogasawara Koh Izumiyama Makoto Saito Masanobu Morioka Akio Mori Takanori Teshima Source Type: research